Pfizer Raises 2026 Revenue Forecast to 62-64 Billion

Teva reported third-quarter adjusted earnings of 86 cents per share on $4.4 billion in sales, beating analyst expectations for both measures, although sales were below the year-earlier level. Pfizer Inc. reported third-quarter revenue of about $16.6 billion, slightly below the year-earlier period but above expectations, and adjusted earnings of 87 cents per share, beating estimates by 14 cents. Lower sales of COVID-19 products and Prevnar were largely offset by growth in Eliquis, Padcev and Vyndaqel. Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted earnings-per-share guidance to $2.95–$3.05, citing performance to date and cost-cutting progress; the earnings outlook includes a licensing charge, and the company increased expected research-and-development spending. Pfizer named Cecile Guegan CFO effective Nov. 1. Separately, Pfizer Ltd. in India reported higher September-quarter revenue and net profit, with net profit rising 65.7% to Rs 313.25 crore, boosted by an exceptional gain tied to the sale of Minipress XL.